Switch theme
Sign up to access all valuation multiples
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the area of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist to prevent, monitor and treat diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
1995
4.1K+
LTM Revenue $288M
LTM EBITDA $80.3M
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dr. Lal PathLabs has a last 12-month revenue of $288M and a last 12-month EBITDA of $80.3M.
In the most recent fiscal year, Dr. Lal PathLabs achieved revenue of $259M and an EBITDA of $78.8M.
Dr. Lal PathLabs expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dr. Lal PathLabs valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $234M | $259M | XXX | XXX | XXX |
| Gross Profit | $151M | $182M | XXX | XXX | XXX |
| Gross Margin | 64% | 71% | XXX | XXX | XXX |
| EBITDA | $61.7M | $78.8M | XXX | XXX | XXX |
| EBITDA Margin | 26% | 30% | XXX | XXX | XXX |
| Net Profit | $40.1M | $27.7M | XXX | XXX | XXX |
| Net Margin | 17% | 11% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Dr. Lal PathLabs's stock price is INR 2702 (or $31).
Dr. Lal PathLabs has current market cap of INR 225B (or $2.6B), and EV of INR 216B (or $2.5B).
See Dr. Lal PathLabs trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $2.6B | XXX | XXX | XXX | XXX | $0.61 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Dr. Lal PathLabs has market cap of $2.6B and EV of $2.5B.
Dr. Lal PathLabs's trades at 8.7x LTM EV/Revenue multiple, and 31.2x LTM EBITDA.
Analysts estimate Dr. Lal PathLabs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Dr. Lal PathLabs and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.5B | XXX | XXX | XXX |
| EV/Revenue | 8.9x | XXX | XXX | XXX |
| EV/EBITDA | 31.5x | XXX | XXX | XXX |
| P/E | 54.0x | XXX | XXX | XXX |
| P/E/Growth | 3.2x | XXX | XXX | XXX |
| EV/FCF | 44.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDr. Lal PathLabs's NTM/LTM revenue growth is 12%
Dr. Lal PathLabs's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $28K for the same period.
Over next 12 months, Dr. Lal PathLabs's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Dr. Lal PathLabs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Dr. Lal PathLabs and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 28% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 40% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $28K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 45% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dr. Lal PathLabs acquired XXX companies to date.
Last acquisition by Dr. Lal PathLabs was XXXXXXXX, XXXXX XXXXX XXXXXX . Dr. Lal PathLabs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Dr. Lal PathLabs founded? | Dr. Lal PathLabs was founded in 1995. |
| Where is Dr. Lal PathLabs headquartered? | Dr. Lal PathLabs is headquartered in India. |
| How many employees does Dr. Lal PathLabs have? | As of today, Dr. Lal PathLabs has 4.1K+ employees. |
| Is Dr. Lal PathLabs publicy listed? | Yes, Dr. Lal PathLabs is a public company listed on NSE. |
| What is the stock symbol of Dr. Lal PathLabs? | Dr. Lal PathLabs trades under LALPATHLAB ticker. |
| When did Dr. Lal PathLabs go public? | Dr. Lal PathLabs went public in 2015. |
| Who are competitors of Dr. Lal PathLabs? | Similar companies to Dr. Lal PathLabs include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Dr. Lal PathLabs? | Dr. Lal PathLabs's current market cap is $2.6B |
| What is the current revenue of Dr. Lal PathLabs? | Dr. Lal PathLabs's last 12-month revenue is $288M. |
| What is the current EBITDA of Dr. Lal PathLabs? | Dr. Lal PathLabs's last 12-month EBITDA is $80.3M. |
| What is the current EV/Revenue multiple of Dr. Lal PathLabs? | Current revenue multiple of Dr. Lal PathLabs is 8.7x. |
| What is the current EV/EBITDA multiple of Dr. Lal PathLabs? | Current EBITDA multiple of Dr. Lal PathLabs is 31.2x. |
| What is the current revenue growth of Dr. Lal PathLabs? | Dr. Lal PathLabs revenue growth between 2023 and 2024 was 10%. |
| Is Dr. Lal PathLabs profitable? | Yes, Dr. Lal PathLabs is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
